Clinical trials: Dementia Alzheimers
Dementia, Alzheimer Disease 1
Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease
This is a Phase 2 study assessing the safety, tolerability and efficacy of intranasal delivery of APH-1105 for the treatment of mild to moderate Alzheimer's in adult.
- Conditions
- Dementia, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- NCT03806478
- Testing
- APH-1105
- Volunteers
- 60 people
- Sponsor
- Aphios
Dementia of the Alzheimer Type, Age-related Cognitive Decline
Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration
DEPEND is an open-label but dosage-masked trial of the retired cholesterol-lowering drug probucol as an agent to increase availability of apolipoprotein E (apoE) in the cerebrospinal fluid (CSF) of cognitively intact older…
- Conditions
- Dementia of the Alzheimer Type, Age-related Cognitive Decline, Mild Cognitive Impairment Due to Alzheimer Disease
- Trial name
- DEPEND (NCT02707458)
- Testing
- Probucol
- Where
- Canada
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Mild Cognitive Impairment (MCI), Subjective Memory Complaint
Validation of a Digital Intervention to Rehabilitate Cognitive Resources
The goal of this clinical trial is to learn if the use of a digital cognitive rehabilitation system named RICORDO, that is flexible and capable of adapting the rehabilitation pathway according to the needs and capacity of the…
- Conditions
- Mild Cognitive Impairment (MCI), Subjective Memory Complaint, Dementia Alzheimer Type
- Trial name
- MI-RICORDO (NCT07064226)
- Testing
- RICORDO, Treatment as Usual (TAU)
- Where
- Italy
- Volunteers
- 102 people
- Sponsor
- Fondazione Don Carlo Gnocchi ETS
Alzheimer Disease
Neuro RX Gamma - Pivotal Phase
The active Neuro RX Gamma device uses non-invasive near-infrared energy delivered to the brain with the intention to improve cognitive functioning and quality of life in patients with moderate to severe Alzheimer's Disease.
- Trial name
- NCT03484143
- Testing
- Active Neuro RX Gamma device
- Where
- 9 sites in United States, Canada
- Volunteers
- 228 people
- Sponsor
- Vielight Inc.
Dementia, Alzheimers Disease
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
This phase 2a study will research the safety and tolerability of Foralumab, a human anti-CD3 antibody. An antibody is a molecule secreted by the immune system. These molecules are created to identify a specific pathogen.
- Conditions
- Dementia, Alzheimers Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
- Trial name
- NCT06489548
- Testing
- Foralumab TZLS-401 50 µg, Foralumab TZLS-401 100 µg
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Brigham and Women's Hospital
Amyotrophic Lateral Sclerosis, Alzheimer's Disease
Advances in Telephone-based Cognitive Screening Procedures
1. Background Cognitive screening procedures via performance-based tests represent an essential, albeit preliminary, element within the diagnostic and interventional process as addressed to patients with chronic neurological…
- Conditions
- Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Lewy Body Dementia, Frontotemporal Degeneration
- Trial name
- TBCS (NCT06337578)
- Testing
- Telephone-based neuropsychological assessment - ALS, Telephone-based neuropsychological assessment - AD, LBD, FTD and CVD, Telephone-based and in-person cognitive screening - NIs
- Where
- Italy
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Istituto Auxologico Italiano
Mild Cognitive Impairment, Alzheimer Disease
The China Longitudinal Aging Study of Cognitive Impairment
Alzheimer's disease (AD) and Vascular dementia (VaD) have become common diseases in the elderly. The burden of dementia is rising in China, with major medical, social and economic impacts.
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Dementia, Vascular, Dementia With Lewy Bodies
- Trial name
- NCT03672448
- Testing
- Naturalistic observation
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Mental Health Center
Alzheimer's Disease
A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.
The objective of this trial was to investigate the effect of galantamine (an acetylcholinesterase inhibitor) on heart rate and PR interval (the time it takes for the heart's electrical impulse to get from the atria to the…
- Trial name
- NCT00309725
- Testing
- galantamine
- Volunteers
- 139 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Traumatic Brain Injury, Cerebral Palsy
Real World Outcomes of Intranasal MuSE Exosomes and Stem Cells in Neurological Regenerative Therapy
This prospective observational study collects real world data on participants receiving regenerative therapies administered internationally and delivered intranasally via the Kurve Therapeutics ViaNase device.
- Conditions
- Traumatic Brain Injury, Cerebral Palsy, Hypoxic Ischemic Encephalopathy, Neurologic Disorders
- Trial name
- MuSE-INSIGHT (NCT07521384)
- Where
- Mexico
- Volunteers
- 36 people
- Sponsor
- Healing Hope International
Alzheimer's Disease
The Prevalence of Vitamin D Deficiency in Patients With Alzheimer's Disease
Recent studies indicate that there is a relationship between cognitive decline and vitamin D deficiency. Up to now, no study has investigated the prevalence of vitamin d deficiency in patient with Alzheimer's disease.
- Trial name
- DEVIT-ALZ (NCT01420315)
- Where
- Turkey (Türkiye)
- Volunteers
- 502 people
- Sponsor
- Saglik Bilimleri Universitesi Gulhane Tip Fakultesi
Preclinical Alzheimer's Disease
Concurrent Aerobic Exercise and Virtual Reality Cognitive Training
The study will implement and test a unique Virtual Reality Cognitive Training (VRCT) combined with concurrent cycling on a recumbent stationary cycle, also known as exergame that seamlessly integrates specific cognitive tasks…
- Trial name
- VRCT (NCT02963415)
- Testing
- Exergame
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Minnesota
Alzheimer's Disease
A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease
Alzheimer's disease (AD) is an ever-increasing public health concern among the aging population and is the most common form of dementia affecting more than 15 million individuals worldwide and around 5 million Europeans.
- Trial name
- NILVAD (NCT02017340)
- Testing
- Nilvadipine
- Where
- 23 sites in France, Germany and 7 more
- Volunteers
- 511 people
- Sponsor
- Prof Brian Lawlor
Active Aging Individuals Aged 65 and Over, Aging
Italian Validation of the dNA Scale and Its Correlation With Neurocognitive Variables
The goal of this experimental multicentric intervention study is to validate, in Italian, the dynamic Neurocognitive Adaptation (dNA) Scale, which has already been validated in English, among a healthy elderly population (aged 65…
- Conditions
- Active Aging Individuals Aged 65 and Over, Aging, Mild Cognitive Impairment (MCI), Dementia
- Trial name
- NCT07533084
- Where
- 8 sites in Italy
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- Neuromed IRCCS
Cognition Disorders
Brain Imaging and Mental Disorders of Aging Intervention
The goal of this project is to determine if a cholinesterase inhibitor is more effective than placebo in delaying cognitive and brain functional decline in people at risk for Alzheimer's disease.
- Trial name
- NCT00267163
- Testing
- donepezil
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- National Institute on Aging (NIA)
Alzheimer's Disease
Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease
This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease who currently receive 10 mg Aricept® (donepezil) per day. This study also will examine the safety and tolerability of the drug.
- Trial name
- NCT00842816
- Testing
- ST101
- Where
- 30 sites in United States, Canada
- Volunteers
- 210 people
- Sponsor
- Sonexa Therapeutics, Inc.
Caregiver Burden, Cognitive Impairment
Evaluating the Efficacy of the Pain Identification and Communication Toolkit
This study will evaluate the Pain Identification and Communication Toolkit (PICT), a multicomponent intervention for caregivers of people with Alzheimer's disease and related dementias (ADRD).
- Conditions
- Caregiver Burden, Cognitive Impairment, Dementia, Alzheimer Disease
- Trial name
- PICT (NCT06168604)
- Testing
- Pain Identification and Communication Toolkit, Health Promotion Program
- Where
- United States
- Volunteers
- 440 people
- Sponsor
- Weill Medical College of Cornell University
Alzheimer's Disease
Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD.
1. To evaluate the diagnostic performance of [18F]-APN-1607 injection PET imaging in detecting uptake patterns consistent with AD neuropathological changes as defined by the National Institute on Aging-Alzheimer's Association…
- Trial name
- NCT07752784
- Testing
- [18F]-APN-1607
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- JYAMS PET Research & Development Limited
Alzheimer Disease
A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers
This study will test two different doses of florbetapir F 18 to determine which dose is best to image amyloid plaques in the brains of Alzheimer's Disease (AD) patients using a positron emission tomography (PET) scanner.
- Trial name
- NCT01565330
- Testing
- florbetapir F 18
- Where
- 3 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
Use of a Mobile Brain-Body Imaging Approach to Evaluate the Effects of Rhythmic Auditory Stimulation on Gait and Brain Function in Alzheimer's Disease
Alzheimer's Disease (AD) is associated with impairments in both gait and cognition, significantly increasing fall risk. Falls are a leading cause of injury-related disability in older adults, and individuals with AD experience a…
- Trial name
- NCT07659964
- Testing
- Metronome
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boston University Charles River Campus
Alzheimer's Dementia, Parkinson Disease(PD)
Eye Gaze Strategies During Facial Emotion Recognition in Neurodegenerative Diseases: Links With Neuropsychiatric Disorders (EYE-ToM Study)
It is commonly admitted that social cognition impairment, like deficit in facial emotion recognition or misinterpretation of others' intentions (Theory of Mind), are associated with social behavior disorders.
- Conditions
- Alzheimer's Dementia, Parkinson Disease(PD), Fronto-Temporal Dementia
- Trial name
- EYE-ToM (NCT04748263)
- Testing
- No intervention. Only survey and normal use of eye-tracking
- Volunteers
- 74 people
- Sponsor
- Centre Hospitalier Princesse Grace
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.